Publications by authors named "Paul Polakis"

Claim this Profile
P
Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response.
Josefa Dela Cruz Chuh, MaryAnn Go, Yvonne Chen, Jun Guo, Hanine Rafidi, Paul Polakis

MAbs· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive Breast Cancer.
Sunil Bhakta, Lisa M Crocker, Yvonne Chen, Meredith Hazen, Melissa M Schutten, Paul Polakis

Mol Cancer Ther· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-Drug Conjugates Derived from Cytotoxic seco-CBI-Dimer Payloads Are Highly Efficacious in Xenograft Models and Form Protein Adducts In Vivo.
Dian Su, Jinhua Chen, Ely Cosino, Josefa Dela Cruz-Chuh, Helen Davis, Paul Polakis

Bioconjug Chem· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive Breast Cancer.
Sunil Bhakta, Lisa M Crocker, Yvonne Chen, Meredith Hazen, Melissa M Schutten, Paul Polakis

Mol Cancer Ther· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers.
Rachana Ohri, Sunil Bhakta, Aimee Fourie-O'Donohue, Josefa Dela Cruz-Chuh, Siao Ping Tsai, Paul Polakis

Bioconjug Chem· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers.
Thomas H Pillow, Melissa Schutten, Shang-Fan Yu, Rachana Ohri, Jack Sadowsky, Paul Polakis

Mol Cancer Ther· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody Drug Conjugates for Cancer Therapy.
Paul Polakis

Pharmacol Rev· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolutionary divergence in the catalytic activity of the CAM-1, ROR1 and ROR2 kinase domains.
Travis W Bainbridge, Venita I DeAlmeida, Anita Izrael-Tomasevic, Cécile Chalouni, Borlan Pan, Paul Polakis

PLoS One· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian Cancers.
Kedan Lin, Bonnee Rubinfeld, Crystal Zhang, Ron Firestein, Eric Harstad, Paul Polakis

Clin Cancer Res· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting LGR5+ cells with an antibody-drug conjugate for the treatment of colon cancer.
Melissa R Junttila, Weiguang Mao, Xi Wang, Bu-Er Wang, Thinh Pham, Paul Polakis

Sci Transl Med· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
Shang-Fan Yu, Bing Zheng, MaryAnn Go, Jeff Lau, Susan Spencer, Paul Polakis

Clin Cancer Res· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Antibody-Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies.
Jyoti Asundi, Lisa Crocker, Jarrod Tremayne, Peter Chang, Chie Sakanaka, Paul Polakis

Clin Cancer Res· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer.
Steven R Leong, Wei-Ching Liang, Yan Wu, Lisa Crocker, Eric Cheng, Paul Polakis

Mol Pharm· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An improved and robust DNA immunization method to develop antibodies against extracellular loops of multi-transmembrane proteins.
Meredith Hazen, Sunil Bhakta, Rajesh Vij, Steven Randle, Dara Kallop, Paul Polakis

MAbs· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Site-specific antibody drug conjugates for cancer therapy.
Siler Panowski, Sunil Bhakta, Helga Raab, Paul Polakis, Jagath R Junutula

MAbs· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering.
Thomas H Pillow, Janet Tien, Kathryn L Parsons-Reponte, Sunil Bhakta, Hao Li, Paul Polakis

J Med Chem· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MAPK pathway inhibition enhances the efficacy of an anti-endothelin B receptor drug conjugate by inducing target expression in melanoma.
Jyoti Asundi, Jennifer A Lacap, Suzanna Clark, Michelle Nannini, Leslie Roth, Paul Polakis

Mol Cancer Ther· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
Ted Lau, Emily Chan, Marinella Callow, Jo Waaler, Jason Boggs, Paul Polakis

Cancer Res· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phosphorylation of Dishevelled by protein kinase RIPK4 regulates Wnt signaling.
XiaoDong Huang, James C McGann, Bob Y Liu, Rami N Hannoush, Jennie R Lill, Paul Polakis

Science· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HectD1 E3 ligase modifies adenomatous polyposis coli (APC) with polyubiquitin to promote the APC-axin interaction.
Hoanh Tran, Daisy Bustos, Ronald Yeh, Bonnee Rubinfeld, Cynthia Lam, Paul Polakis

J Biol Chem· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2.
C Andrew Boswell, Eduardo E Mundo, Ron Firestein, Crystal Zhang, Weiguang Mao, Paul Polakis

Br J Pharmacol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential effects of predosing on tumor and tissue uptake of an 111In-labeled anti-TENB2 antibody-drug conjugate.
C Andrew Boswell, Eduardo E Mundo, Crystal Zhang, Shannon L Stainton, Shang-Fan Yu, Paul Polakis

J Nucl Med· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reversible modification of adenomatous polyposis coli (APC) with K63-linked polyubiquitin regulates the assembly and activity of the β-catenin destruction complex.
Hoanh Tran, Paul Polakis

J Biol Chem· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The melanosomal protein PMEL17 as a target for antibody drug conjugate therapy in melanoma.
Youjun Chen, Cecile Chalouni, Christine Tan, Robyn Clark, Rayna Venook, Paul Polakis

J Biol Chem· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drugging Wnt signalling in cancer.
Paul Polakis

EMBO J· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis